Tag archives: Life Sciences

Ontario consults on changes to streamline drug formulary listing and reduce government payments to pharmacies

The Ontario Ministry of Health and Long-Term Care (the Ministry) has proposed draft amendments to Regulations made under the Ontario Drug Benefit Act (ODBA) and the Ontario Drug Interchangeability and Dispensing Fee Act. The proposed changes are intended to reduce technical requirements for listing a product on the Ontario formulary and align policies with industry standards and other provinces. The consultation period will close on November 27, 2019.

The proposed changes

Key changes to the Regulations include:

  • Remove the requirement for the Drug Notification Form (DNF) from formulary drug submissions. A DNF is a form submitted
Continue Reading

Pharma in brief – TMOB dismisses section 45 proceedings for the trade-mark REMODULIN

Case: Blake, Cassels & Graydon LLP v United Therapeutics Corporation, 2017 TMOB 9

Trade-Mark: REMODULIN

Nature of case: Summary expungement proceedingpursuant to section 45 of Trade-marks Act

Successful party: United Therapeutics Corporation

Date of decision: January 26, 2017

Summary

The Trademarks Opposition Board (TMOB) accepted United Therapeutics Corporation’s evidence of use of the trade-mark REMODULIN in association with pharmaceutical preparations in the treatment of cardiovascular, pulmonary and vascular diseases, and maintained both registrations.

The TMOB accepted United’s evidence of use based on sample invoices and photographs of individual packaging and shipping boxes. The TMOB further accepted the affiants’ evidence … Continue Reading

LexBlog